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Recently, we reported a highly active regimen in advanced gastric cancer including a weekly administration of cisplatin,
epidoxorubicin, leucovorin, 5-ﬂuorouracil with the support of ﬁlgrastim. In order to simplify the administration and to decrease
the toxicity of these drugs, mainly epidoxorubicin-induced alopecia, we designed a regimen including an infusional 5-
ﬂuorouracil schedule according to the de Gramont regimen, cisplatin and mitomycin C replacing epidoxorubicin. Forty-ﬁve
patients with advanced or metastatic gastric cancer were treated with cisplatin 50 mg m
72 i.v. on day 1, every 2 weeks, 6S-
stereoisomer-leucovorin 100 mg m
72 i.v. followed by 5-ﬂuorouracil 400 mg m
72 i.v. bolus and 600 mg m
72 i.v. in a 22-h
infusion, on days 1 and 2, every 2 weeks, and mitomycin C 7 mg m
72 i.v. bolus on day 2, every 6 weeks. Grades 3–4
toxicities (National Cancer Institute-Common Toxicity Criteria) consisted mainly of neutropenia and thrombocytopenia. Five
patients had a complete response and 16 had a partial response for an overall response rate of 46.7% (95% conﬁdence
interval, 32.1–61.2%). The median survival was 11 months. The combination of cisplatin, 5-ﬂuorouracil and leucovorin
according to de Gramont, and mitomycin C seems to be an active and safe regimen in the treatment of advanced gastric
cancer. Because of its low cost it may be suggested for patients not enrolled into clinical trials.
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Although several new chemotherapeutic drugs have been recently
introduced into clinical practice, metastatic gastric carcinoma still
remains an incurable disease with poor median survival ranging
from 6 to 8 months (Schipper and Wagener, 1996). During the last
decade, various randomized trials have demonstrated the improve-
ment of 5-ﬂuorouracil (5-FU)-based regimens in terms of overall
survival and quality of life in patients with advanced gastric cancer
in comparison to the best supportive care (Murad et al, 1993;
Pyrhonen et al, 1995; Glimelius et al, 1997). Moreover, in phase
II studies the combination of cisplatin (CDDP) and 5-FU showed
promising results both in the metastatic disease (Lacave et al,
1991), and in the preoperative setting (Rougier et al, 1994). In
advanced gastric cancer, two phase III randomized studies
compared the efﬁcacy of a combination of CDDP and infusional
5-FU (FP) to other 5-FU-based chemotherapies. In the ﬁrst study
(Kim et al, 1993), FP achieved a signiﬁcantly higher response rate
and a longer time to progression than 5-FU, doxorubicin (ADR),
and mitomycin C (MMC) (FAM regimen) or infusional 5-FU,
but survival was not signiﬁcantly ameliorated. In the other study,
Vanhoefer et al (2000) compared the efﬁcacy and tolerability of
FP or etoposide, folinic acid, and 5-FU (ELF) with that of the stan-
dard 5-FU, ADR, and sequential high-dose methotrexate
(FAMTX). However, all three treatments showed modest clinical
activity and comparable toxicity, neutropenia being the most
frequent side-effect.
In 1997, we reported interesting results in the treatment of
advanced gastric cancer with an intensive weekly low dose 5-FU,
epidoxorubicin (epiADR), CDDP, 6S-stereoisomer-leucovorin
(LV), and bone marrow support with the haemopoietic growth
factor ﬁlgrastim (Cascinu et al, 1997). The choice of these drugs
and schedule was made based on the following: 5-FU, epiADR
and CDDP remain the most active single agents in gastric cancer
(Schipper and Wagener, 1996); 5-FU and CDDP are potentially
synergistic (Leichman and Berry, 1991); LV can enhance 5-FU
activity (Arbuck et al, 1987); weekly administration allows more
drug to be administered per unit time, which minimizes side effects
(Young, 1990); ﬁlgrastim may contribute to perform weekly
administrations of drugs reducing the incidence of neutropenia.
This weekly intensive regimen conﬁrmed its activity also in locally
advanced gastric cancer enabling resection on half of previously
inoperable tumour with a moderate toxicity (Cascinu et al,
1998), and now a randomized trial in the adjuvant setting is being
carried out in Italy.
A potential drawback of this weekly regimen may be the
economic cost of ﬁlgrastim administration. While in preoperative
chemotherapy or in the adjuvant setting it may be justiﬁable, it
may not be cost-effective in the advanced disease. Furthermore,
in our regimen the schedule of 5-FU given by bolus injection
may not be optimal. The combination of 5-FU and LV according
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FU; furthermore, the continuous infusion increases the time expo-
sition of tumour cells to 5-FU, which may translate into a better
oncolytic effect (de Gramont et al, 1997).
Based on these considerations and on the results of a bi-weekly
infusional administration of 5-FU, according to de Gramont et al
(1997), we tested a new combination associating CDDP and MMC
to the de Gramont regimen. While the contribution of epiADR to
the combination of 5-FU and CDDP is unclear, MMC has been
reported to be one of the most active cytotoxic drugs in this disease
(Schnall and Macdonald, 1993). Another peculiar aspect of MMC is
the lower incidence of alopecia than that induced by epiADR. Herein,
we reported the results of a multicentre phase II study in order to
assess safety and efﬁcacy of bi-weekly CDDP and de Gramont regi-
men in combination with MMC.
PATIENTS AND METHODS
Patient selection
Patients with histologically conﬁrmed unresectable locally advanced
and/or metastatic gastric carcinoma were eligible for the study.
Patients thought to have potentially curable disease by resection
of the primary tumour were not eligible. Patients were required
to have measurable disease, deﬁned as the presence of lesion iden-
tiﬁed bidimensionally by CT scan. Patients with nonmeasurable
disease as the only reference were not included, and in the case
of radiotherapy to individual sites of disease, they were not consid-
ered evaluable for response. Other eligibility criteria were age 470
years, Eastern Cooperative Oncology Group (ECOG) performance
status 0 to 2, and normal liver (serum bilirubin 51.5 mg dl
71),
renal (serum creatinine 51.5 mg dl
71) and bone marrow (neutro-
phils 42610
9 l
71, platelets 4100610
9 l
71) functions. Informed
consent was obtained from all participants after the nature of the
study had been fully explained. The protocol was approved by
the local ethic committees.
Chemotherapy
The treatment schedule consisted of CDDP 50 mg m
72 as a 30-
min infusion, on day 1; LV 100 mg m
72 diluted in 250 ml of
normal saline solution in a 2-h infusion followed by 5-FU
400 mg m
72 i.v. bolus and 5-FU 600 mg m
72 in a 22-h infu-
sion, repeated for 2 consecutive days; MMC 10 mg m
72 as a
bolus injection, on day 2, every 42 days. Subsequent to the ﬁrst
10 patients developing severe toxicity, the planning dose of
MMC was reduced to 7 mg m
72 (cumulative total dose of
28 mg m
72, maximum 56 mg), as suggested previously by Ross
et al (1997). Standard intravenous hydration was used: 2 h
before initiation of the CDDP infusion, patients received
1500 ml of 0.9% sodium chloride to which 20 mequiv of potas-
sium chloride and 15 mequiv of magnesium sulphate were
added. Post-hydration was continued for 2 h with 1000 ml of
normal saline solution. As antiemetic regimen, all patients
received dexamethasone 20 mg in 50 ml of saline solution given
as an intravenous infusion over 15 min, 45 min before CDDP,
and 5HT-3 antagonists (ondansetron 8 mg or tropisetron 5 mg)
in 50 ml of normal saline as intravenous infusion over 15 min.
Treatment was repeated every 14 days for a minimum of six
cycles and stopped in case of unacceptable toxicity, disease
progression, or patient refusal. Treatment was administered
through a central venous line, or a venous totally implantable
port, connected with external pumps.
Evaluation of toxicity and response
Chemotherapy toxicity was assessed every 2 weeks according to
the National Cancer Institute Common Toxicity Criteria
(National Cancer Institute–CTC) (1990). Patients were to be
removed from the study for any treatment delay longer than 3
weeks. Chemotherapy was delayed until recovery if neutrophils
decreased to 41.5610
9 l
71, or platelet count decreased to
4100610
9 l
71. A 25% dose reduction of chemotherapeutic
drugs was mandatory in case of grade 4 neutropenia, grade
3–4 thrombocytopenia, grade 2–3 mucositis, diarrhoea, or
hand-foot syndrome. Treatment was stopped in case of grade 4
mucositis, diarrhoea, or hand-foot syndrome. In the presence
of other grade 4 NCI–CTC toxicities, patients should be with-
drawn from the study. Tumour response was measured
according to the World Health Organization (WHO) criteria,
and was performed after six and 12 cycles of therapy. Histologic
conﬁrmation at endoscopy of tumoural resolution was required
to determine a complete response at the primary site.
Statistical methods
This was a multicentre phase II study. The primary end-points
were to determine the response rate and toxicity. Secondary
objectives were to measure the duration of response and survival.
This study followed the minimax two-stage phase II design. The
treatment program was designed to reject a response rate less
than 20% (p0) and to provide a statistical power of 90% in
assessing the activity of the regimen (in terms of response rate)
as 40% (p1) (p1–p0=20%) for an alpha error less than 0.10
(Simon, 1989). The 95% exact conﬁdence interval (CI) for
response was calculated. Survival time was calculated from the
onset of chemotherapy until death or the last visit for patients
alive. Duration of response was calculated from the date of
response to progression or death. Patients survival was examined
using the Kaplan-Meier product limit method (Kaplan and
Meier, 1958).
RESULTS
Forty-ﬁve consecutive patients were entered into the study. At May
2001, the median follow-up duration from the start of treatment
was 18 months (range 12 to 23 months). The characteristics of
the patients are summarized in Table 1. Only three patients had
locally advanced disease (two primary gastric cancers and one
anastomotic relapse).
Toxicity
A total of 330 cycles was delivered and the median number of
cycles for patient who received treatment was six (range, 1 to
13). Seventeen patients received chemotherapy without any modi-
ﬁcation of the planned dose; in the other 28 patients treatment was
modiﬁed due to toxicity (mainly, haematological). All 45 patients
were evaluable for toxicity (Table 2). Grade 3–4 neutropenia
occurred in 21%, thrombocytopenia in 16%, and mucositis in
3% of patients. Other toxicities were mainly mild: nausea/vomiting,
mucositis, diarrhoea. Grade 1–2 alopecia occurred in 26% of
patients. No patient had treatment related death.
Response and survival
Objective tumour response was observed in 21 of 45 patients for a
response rate of 46.7% (95% CI, 32.1–61.2%) (Table 3). Five
patients achieved a complete response and 16 a partial response.
The median duration of response was 7 months (range, 3–10).
The response rate was not signiﬁcantly affected by the number of
metastatic sites (1 vs 2), nor by the type of metastases. Eleven
patients had stable disease, whereas in 13 patients disease
progressed while on therapy. The median survival of all patients
was 11 months, with 1 and 2 year survivals of 45 and 10%, respec-
tively.
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Our three drugs combination is a well tolerated and effective pallia-
tive chemotherapeutic regimen, and compares well with our previous
intensive weekly regimen (Cascinu et al, 1997) in terms of activity,
with 46% of response rate and a median survival of 11 months.
Although the non randomized design of this study suggests caution
in the interpretation of results, the objective tumour response rate
is within the conﬁdence limits observed in the cohort of patients
treated previously with the intensive weekly regimen (Cascinu et al,
1997). Wilke et al (1996) showed that infusional 5-FU can be safely
combined with bi-weekly CDDP in advanced gastric cancer. More
recently, Kretzschmar et al (2000) reported the results of a weekly
high-dose infusional 5-FU combined with MMC. In 34 evaluable
patients, they obtained 11 objective response (37%) with a median
survival time of 7 months. The survival reported in the present study
is comparable to that obtained with the most intensive regimen, and
clearly better than that reported with the combination of 5-FU with
CDDP or MMC alone (Schnall and Macdonald, 1993; Wilke et al,
1996; Kretzschmar et al, 2000). Recently, Mitry et al (2000) reported
interesting results with a similar regimen (de Gramont or its simpli-
ﬁed modiﬁcation plus CDDP) to that adopted in our study, but
without the administration of MMC. A response rate of 46.1 and
of 55.6% was achieved in 13 patients with gastric cancer and nine
patients with gastro-oesophageal junction cancer, respectively. In this
trial, a severe thrombocytopenia was observed in only one patient out
of 39 compared with 21% of patients in the present report, an effect
likely to be due to the administration of MMC in our study. The
comparable efﬁcacy and better tolerability of a CDDP and de
Gramont regimen without the addition of MMC may warrant further
evaluation.
Recently, the Royal Marsden Hospital reported the results of a
phase II study on oesophago-gastric cancer patients treated with
CDDP, infusional 5-FU and epiADR (ECF regimen) (Findlay et al,
1994). The activity of this regimen (71% of response rate) and the
acceptable toxicity contributed to launch a large randomized trial
in which ECF was compared to the standard FAMTX. ECF proved
to be signiﬁcantly better than FAMTX in terms of overall response
rate (45 vs 21%, respectively; P=0.0002), median survival (8.8 versus
5.7 months, respectively; P=0.0009), quality of life and cost-effective-
ness (Webb et al, 1997). In a second randomized trial on advanced
oesophago-gastric cancer patients, the ECF regimen was compared
to MCF, with MMC used in substitution of epiADR. The preliminary
results of the study showed similar activity with both MCF and ECF
(Ross et al, 1999).
Although MMC has only limited single-agent activity in colorec-
tal cancer, in this disease the addition of MMC to 5-FU improved
the response rate and progression-free survival relative to 5-FU
(Ross et al, 1997), suggesting the possibility of a clinical synergism
between MMC and infusional 5-FU, similarly to that obtained with
CDDP (Becker et al, 1997. Moreover, the use of MMC is correlated
with a lower incidence of alopecia than that given by epiADR. If
we consider that alopecia is a relevant psychosocial problem for
cancer patients, and if MMC is similarly active than epiADR in
gastric cancer, it would be advantageous for patients to receive a
regimen including MMC instead of epiADR. Interestingly, in the
study comparing ECF with MCF, quality of life was superior with
ECF (Ross et al, 1999); but it is generally hard to understand how
important on health status may be a single aspect like alopecia
when the global health-functioning aspect is translated into a score.
New cytotoxic agents, such as irinotecan, paclitaxel and docetax-
el could be a more appealing approach for the treatment of
advanced gastric cancer (Kollmannsberger et al, 2000; Mavroudis
et al, 2000; Roth et al, 2000). Docetaxel obtained a 20% response
rate as ﬁrst-line treatment in 37 advanced gastric patients (Sulkes
et al, 1994) with a median survival time of 7 months. However,
at the dose of 100 mg m
72 every 3 weeks, ﬁlgrastim had to be
given for 7 days. When lower doses of docetaxel in a weekly sche-
dule were attempted, no clinical relevant results were found
(Graziano et al, 2000). Preliminary data on docetaxel (at a dose
of 85 mg m
72) combined with CDDP every 3 weeks seem to be
promising with a response rate of 56% (Roth et al, 2000). Simi-
larly, Kollmannsberger et al (2000) reported a response rate of
51% combining paclitaxel with CDDP and 5-FU.
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Table 1 Patient characteristics
Characteristics No of patients
Total 45
Sex
Male 29
Female 16
Age
Median (range) 62 (41–71)
Performance status (ECOG)
01 9
12 4
22
Prior surgery
None 16
Curative 27
Palliative 2
Sites of primary tumour
Proximal stomach 8
Body 28
Distal stomach 9
Involved site
Stomach 16
Liver 12
Abdomen/peritoneum 18
Lymph nodes 16
Local relapse 7
Others 6
No involved sites
11 8
21 7
531 0
Previous adjuvant chemotherapy
Yes 12
No 33
Table 2 Treatment toxicity according to NCI–CTC: maximum toxicity
experienced by each patient (%)
Grade (NCI–CTC)
Toxicity 1 2 3 4
Neutropenia 11 42 18 3
Thrombocytopenia 26 16 8 8
Anaemia 11 39 – –
Nausea/vomiting 29 24 – –
Mucositis 20 3 3 –
Diarrhoea 3 10 – –
Table 3 Tumour response
Response No %
Complete response 5 11.1 46.7%
(95% CI, 32.1–61.2%)
Partial response 16 35.6
Stable disease 11 24.4
Progressive disease 13 28.9
5-FU, CDDP and mytomycin in advanced gastric cancer
S Cascinu et al
215
ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 213–217However, the results obtained with these newer schedules seem
to be comparable with those of our regimen. New drugs such as
docetaxel and paclitaxel may increase the economic cost of
chemotherapy, as a consequence of the major cost of such drugs,
of the more frequent incidence of severe toxicity, mainly haemato-
logical, which may require in most cases the preventive use of
haemopoietic growth factors and the need of longer hospitaliza-
tion.
In conclusion, our data show that 5-FU, MMC and CDDP can
be safely administered in combination, and that such a combina-
tion may have a therapeutic activity, similar to more aggressive
regimens, or regimens including new and much more expensive
drugs. In metastatic gastric cancer patients not eligible for entry
into clinical trials, this regimen may be a reasonable option. A
multicentre cooperative group is now evaluating this regimen in
a randomized trial on patients with advanced gastric cancer.
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